Agomab Therapeutics Nv (AGMB) Annual Income Statement

Annual · GAAP · USD millions
Access AGMB quarterly income statements →
The income statement data below highlights shifts in Agomab Therapeutics Nv's operating performance over recent quarters.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AGMB/income-statements
https://api.csimarket.com/api/v1/companies/AGMB/fundamentals
https://api.csimarket.com/api/v1/companies/AGMB/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
2025
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing14.33
Research and Development Expense54.74
Other Operating Expense / -Income-2.68
Total operating costs including COS66.39
Operating income / -loss-66.39
Net Interest (-)Expense / Income0.00
Other loss / -income0.00
Total costs & expenses70.05
Income & Taxes
Income / -loss before income taxes-70.05
Income after income taxes-70.05
Income / -loss from continuing operations-70.05
Net income / -loss-70.05
Income / -loss to shareholder-70.05
EBIT-70.05
EBITD-70.05
EBITDA-70.05
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Basic shares outstanding (Mill. of Units)0.54
Diluted Net EPS0.00
Diluted average shares (Mill. of Units)0.54
4 historic quarters locked

Sign in to unlock the full Agomab Therapeutics Nv income statement history.

About AGMB Annual Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-K filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-K filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API Connect Your AI